Click here to access the guidelines/NICE algorithm N&WICS - TA507 - Sofosbuvir-velpatasvir-voxilaprevir - Chronic hepatitis C Before providing patient identifiable data on this form, please confirm that the patient (or in the case of a minor or vulnerable adult with the parent/legal guardian/carer) has given appropriate explicit consent for sensitive personal information on this form to be passed to the CCG and/or CSU for processing this funding request and validating subsequent invoices. Consent given: If there is more than one NICE-approved treatment available, a discussion between the responsible clinician and the patient has taken place about the advantages and disadvantages of the treatments available. This has taken into consideration therapeutic need and whether or not the patient is likely to adhere to treatment. The most appropriate, least expensive, will be chosen (taking into account administration costs, dosage and price per dose) unless an order of preference is stated in the TAs. **Patient Practice** Trust: NHS No: Name: **Patient** Consultant **Practice** Hospital Making Postcode: No: Request: Patient's **Practice** Initials and Code: DoB: **Notification** Contact Email (@NHS.net account ONLY) name & Address: number: Provider: Start date ☐ Private ☐ NHS of Supplier: Sub-Type: ☐ Homecare ☐ Hospital requested treatment: (if applicable) By completing this form, you confirm that you intend to use the requested medicinal product described below as agreed in the local commissioning statement. Any requests which fall outside of this use will require an individual funding request (IFR). For support regarding IFRs, please contact: norfolkicd@nhs.net For support regarding the criteria listed below, please contact: norfolknontariff@nhs.net Please indicate whether patient meets the following NICE criteria: Please tick 1. Sofosbuvir-velpatasvir-voxilaprevir is recommended as an option for treating chronic hepatitis C in adults, only if it is used as specified in table 1 and the company provides the drug at the same price or lower than that agreed with the Commercial Medicines Unit. • Table 1 Sofosbuvir-velpatasvir-voxilaprevir for treating chronic hepatitis C Treatment history · Hepatitis C virus genotype · Liver disease stage • Recommendation □Yes □No · Previous direct-acting antivirals

Table 1 Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C

Treatment history

Hepatitis C virus genotype

Liver disease stage

Recommendation

Previous direct-acting antivirals

1–6

With or without compensated cirrhosis

Recommended for 12 weeks

No direct-acting antivirals

3

With or without compensated cirrhosis

Recommended for 8 weeks

Recommended for 8 weeks

Lit is recommended that the decision to treat and prescribing decisions are made by multidisciplinary

teams in the operational delivery networks put in place by NHS England, to prioritise treatment for people with the highest unmet clinical need.		│ □Yes □No
3. As per NICE guidance, treatment should normally be started with the least expensive drug (considering the dose required, price per dose and any additional administration costs).		
Please confirm that the choice of drug is considered the most cost-effective treatment for this individual patient, noting that alternative treatment options recommended by NICE may be lower in cost, including the use of biosimilar medications if applicable.		□Yes □No
Where an alternative lower cost treatment is available and has not been tried by the patient, please confirm that the clinical rationale for prescribing has been included in the patients' medical record for the purpose of auditing.		
4. The product is being used as described by local commissioning position.		
4. The product is being used as described by local commission	ming position.	∐Yes ∐No
I confirm that the patient meets the criteria for treatment	<u> </u>	∐Yes ∐No
,	<u> </u>	∐Yes ∐No
I confirm that the patient meets the criteria for treatment		∐Yes ∐No
I confirm that the patient meets the criteria for treatment Name of person completing:	Contact Details:	∐Yes ∐No